701 related articles for article (PubMed ID: 23400082)
1. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes.
Baek JS; Cho HJ; Cho SW; Kim CG; Kim JW
Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082
[TBL] [Abstract][Full Text] [Related]
2. Comparison of intravitreal ranibizumab in phakic and pseudophakic neovascular age-related macular degeneration patients with good baseline visual acuity.
Ozkaya A; Alkin Z; Yazici AT; Demirok A
Retina; 2014 May; 34(5):853-9. PubMed ID: 24141904
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.
Saito M; Iida T; Kano M
Retina; 2012 Jul; 32(7):1250-9. PubMed ID: 22446886
[TBL] [Abstract][Full Text] [Related]
4. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics.
Rush RB; Simunovic MP; Vandiver L; Aragon AV; Ysasaga JE
Retina; 2014 May; 34(5):846-52. PubMed ID: 24240560
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal ranibizumab injections with and without pneumatic displacement for treating submacular hemorrhage secondary to neovascular age-related macular degeneration.
Cho HJ; Koh KM; Kim JH; Kim HS; Han JI; Lew YJ; Lee TG; Kim JW
Retina; 2015 Feb; 35(2):205-12. PubMed ID: 25105310
[TBL] [Abstract][Full Text] [Related]
6. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
Kang HM; Kwon HJ; Yi JH; Lee CS; Lee SC
Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050
[TBL] [Abstract][Full Text] [Related]
7. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.
Yamazaki T; Koizumi H; Yamagishi T; Kinoshita S
Ophthalmology; 2012 Aug; 119(8):1621-7. PubMed ID: 22551738
[TBL] [Abstract][Full Text] [Related]
8. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
[TBL] [Abstract][Full Text] [Related]
9. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB
Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
[TBL] [Abstract][Full Text] [Related]
10. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab.
Cho HJ; Kim CG; Yoo SJ; Cho SW; Lee DW; Kim JW; Lee JH
Am J Ophthalmol; 2013 Jan; 155(1):118-126.e1. PubMed ID: 23022163
[TBL] [Abstract][Full Text] [Related]
11. Ranibizumab for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy: one-year results.
Mimoun G; Caillaux V; Querques G; Rothschild PR; Puche N; Souied EH
Retina; 2013 Mar; 33(3):513-21. PubMed ID: 23400081
[TBL] [Abstract][Full Text] [Related]
12. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
Brown DM; Chen E; Mariani A; Major JC;
Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
[TBL] [Abstract][Full Text] [Related]
13. Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials.
Weinberg DV; Shapiro H; Ehrlich JS
Ophthalmology; 2013 Jun; 120(6):1278-82. PubMed ID: 23453513
[TBL] [Abstract][Full Text] [Related]
14. Association between foveal microstructure and visual outcome in age-related macular degeneration.
Shin HJ; Chung H; Kim HC
Retina; 2011 Sep; 31(8):1627-36. PubMed ID: 21606888
[TBL] [Abstract][Full Text] [Related]
15. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
[TBL] [Abstract][Full Text] [Related]
16. Results of intravitreal ranibizumab with a prn regimen in the treatment of extrafoveal and juxtafoveal neovascular membranes in age-related macular degeneration.
Giacomelli G; Giansanti F; Finocchio L; Biagini I; Bacherini D; Virgili G; Menchini U
Retina; 2014 May; 34(5):860-7. PubMed ID: 24756034
[TBL] [Abstract][Full Text] [Related]
17. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy.
Cho HJ; Baek JS; Lee DW; Cho SW; Kim CG; Kim JW
Retina; 2013; 33(10):2126-32. PubMed ID: 23609123
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of spectral-domain optical coherence tomography features in assessment of visual prognosis in eyes with neovascular age-related macular degeneration treated with ranibizumab.
Mathew R; Richardson M; Sivaprasad S
Am J Ophthalmol; 2013 Apr; 155(4):720-6, 726.e1. PubMed ID: 23317653
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab in the management of neovascular age-related macular degeneration: effect of baseline visual acuity.
El-Mollayess GM; Mahfoud Z; Schakal AR; Salti HI; Jaafar D; Bashshur ZF
Retina; 2013 Oct; 33(9):1828-35. PubMed ID: 23615342
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab for neovascular age-related macular degeneration in China.
Li X; Hu Y; Sun X; Zhang J; Zhang M;
Ophthalmology; 2012 Oct; 119(10):2087-93. PubMed ID: 22818896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
